A Study of MHB036C for Advanced Solid Tumor - Trial NCT06373406
Access comprehensive clinical trial information for NCT06373406 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Minghui Pharmaceutical (Hangzhou) Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Minghui Pharmaceutical (Hangzhou) Ltd
Timeline & Enrollment
Phase 1/2
May 18, 2023
Dec 01, 2024
Primary Outcome
Incidence of participants with adverse events (AE),Number of participants with dose-limiting toxicity (DLT)
Summary
Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of
 MHB036C in advanced malignant tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06373406
Non-Device Trial